Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has considered the creation of an independent review board similar to the US Defense Health Board to oversee the joint medical readiness of the (a) NHS, (b) Defence Medical Services and (c) private healthcare in the UK.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
There are currently no plans to create an independent review board to oversee joint medical readiness in the United Kingdom.
The Ministry of Defence and the Department of Health and Social Care’s Partnership Board facilitate joint working across the UK to address issues relating to the health of, and healthcare for, Armed Forces personnel and veterans. The Partnership Board meets three times a year, to ensure that departments and stakeholders meet the requirements of the Armed Forces Covenant and to improve the health and healthcare of the UK Armed Forces before, during, and after deployment, and of their families.
With oversight from the Partnership Board, the Department of Health and Social Care will work closely with the Ministry of Defence to consider the recommendations of The Strategic Defence Review 2025, to ensure that the National Health Service is resilient and prepared to meet the demands of any potential future conflict.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has a defined role for the NHS in supporting (a) medical care and (b) rehabilitation for armed forces personnel injured in conflicts.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The National Health Service in England provides a range of secondary and tertiary care services for the Armed Forces personnel, including medical care for Armed Forces personnel injured in conflicts.
A partnership agreement is in place between NHS England and the Ministry of Defence that sets out how the Ministry of Defence and NHS England will work together in the planning and organising of the delivery of healthcare and supporting policies.
The Department of Health and Social Care will work closely with the Ministry of Defence to consider the recommendations of The Strategic Defence Review 2025 to ensure the national health system is resilient and prepared to meet the demands of any potential future conflict.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the impact of NHS staffing shortages on the availability of medical Reservists for the armed forces.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
No specific assessment has been made. NHS Employers, which is part of the NHS Confederation and supports workforce development across the National Health Service, runs a programme that is funded by the Department of Health and Social Care and the Ministry of Defence to encourage NHS organisations to be supportive and flexible employers when it comes to people joining the Armed Forces Reserve. This ensures that people with the critically important skills that the reserves are looking for, such as doctors, are able to train and deploy when needed.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has considered a Sponsored Reserve model or similar arrangement to enable NHS clinicians to contribute directly to Defence Medical Services while maintaining NHS employment.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
There have been no formal considerations for the implementation of a Sponsored Reserve model within the National Health Service. The Department of Health and Social Care, in partnership with the Ministry of Defence, is focused on growing and maintaining the Active Armed Forces reserve and works with NHS organisations to enable individuals to train and deploy when needed.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to take steps with the Secretary of State for Defence to create a formal framework for supporting NHS-employed clinicians who serve as medical Reservists.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Clinicians who serve as Reservists play a vital role in supporting both the National Health Service and the Armed Forces. The Department of Health and Social Care and the Ministry of Defence work with NHS Employers to ensure that NHS organisations are supportive and flexible when it comes to people joining the Armed Forces Reserve, and to enable individuals to train and deploy when needed. All NHS trusts are signed up to the Armed Forces Covenant and all have been awarded an Employer Recognition Scheme award to reflect their commitment to supporting our Armed Forces, including the Reserves.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of increases in National Insurance contributions on the financial sustainability of charitable hospices and the delivery of end-of-life care services.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
We took the necessary decisions to fix the foundations in the public finances at the Autumn Budget, enabling the Spending Review settlement of a £22.6 billion increase in resource spending for the Department from 2023/24 outturn to 2025/26.
The employer National Insurance contribution rise was implemented in April 2025, and planning guidance published on 30 January 2025 sets out the funding available to integrated care boards and the overall approach to funding providers for the 2025/26 financial year. It takes into account a variety of pay and non-pay factors and pressures on providers of secondary healthcare, including charitable hospices. Further information on the planning guidance is available at the following link:
https://www.england.nhs.uk/publication/2025-26-priorities-and-operational-planning-guidance/
We are supporting the hospice sector with a £100 million capital funding boost for adult and children’s hospices in England, to ensure they have the best physical environment for care. I am delighted that the first £25 million tranche of that funding, which Hospice UK kindly allocated and distributed to hospices throughout England, was fully spent by hospices on capital projects. An additional £75 million will be allocated in the coming weeks for use in 2025/26.
We are also providing £26 million of revenue funding to support children and young people’s hospices for 2025/26. This is a continuation of the funding which until recently was known as the children and young people’s hospice grant.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of changes to hospice funding on the sustainability of end-of-life care services.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Palliative care services are included in the list of services an integrated care board (ICB) must commission. This promotes a more consistent national approach and supports commissioners in prioritising palliative and end of life care. To support ICBs in this duty, NHS England has published statutory guidance and service specifications.
Whilst the majority of palliative and end of life care is provided by National Health Service staff and services, we recognise the vital part that voluntary sector organisations, including hospices, also play in providing support to people at end of life and their loved ones.
In recognition of this, we are supporting the hospice sector with a £100 million capital funding boost for adult and children’s hospices in England for 2024/25 and 2025/26, to ensure they have the best physical environment for care.
Additionally, children and young people’s hospices will receive £26 million in revenue funding for 2025/26. This is a continuation of the funding which until recently was known as the children and young people’s hospice grant.
In February, I met with key palliative care and end of life care and hospice stakeholders, in a roundtable format, with a focus on long-term sector sustainability within the context of our 10-Year Health Plan.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to his Department's press release entitled New services for patients under record pharmacy funding deal, published on 31 March 2025, what proportion of the additional funding for community pharmacies was allocated to meet the cost of increases to (a) employer National Insurance Contributions (b) business rates and (c) National Minimum Wage in (i) 2024/25 and (ii) 2025/26.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
We have taken the necessary decisions to fix the foundations in the public finances at the Autumn Budget, which enabled the Spending Review settlement of a £22.6 billion increase in resource spending for the Department from 2023/24 outturn to 2025/26.
The Department has considered the increases in the National Living Wage and employer national insurance when consulting on the funding arrangements for community pharmacy. We have now agreed with Community Pharmacy England to increase the community pharmacy contractual framework to £3.073 billion from April 2025. This deal represents the largest uplift in funding of any part of the National Health Service, at over 19% across 2024/25 and 2025/26.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the cost to community pharmacies of changes in the level of (a) employer National Insurance contributions, (b) business rates and (c) the National Minimum Wage from 1 April 2025.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
We have taken the necessary decisions to fix the foundations in the public finances at the Autumn Budget, which enabled the Spending Review settlement of a £22.6 billion increase in resource spending for the Department from 2023/24 outturn to 2025/26.
The Department has considered the increases in the National Living Wage and employer national insurance when consulting on the funding arrangements for community pharmacy. We have now agreed with Community Pharmacy England to increase the community pharmacy contractual framework to £3.073 billion from April 2025. This deal represents the largest uplift in funding of any part of the National Health Service, at over 19% across 2024/25 and 2025/26.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support the (a) development and (b) approval of (i) second- and third-line tyrosine kinase inhibitors and (ii) other targeted therapy options for patients with ROS1-positive cancer; and whether his Department has had recent discussions with (A) the National Institute for Health and Care Excellence and (B) pharmaceutical companies on encouraging clinical trial funding in this area.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body that develops recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS based on an assessment of clinical and cost effectiveness. The NICE evaluates all new licensed cancer medicines and aims wherever possible to issue recommendations close to the time of licensing. The NHS in England is legally required to fund treatments recommended by the NICE. The NICE published guidance that recommends the tyrosine kinase inhibitors crizotinib and entrectinib for use in the treatment of people with ROS1 positive advanced non-small cell lung cancer who have not previously been treated with ROS1 inhibitors. These treatments are now routinely funded by the NHS for eligible patients.
The Department has had no discussions with the NICE or pharmaceutical companies on encouraging clinical trial funding in this area. The Department is working closely with the NHS, industry, academia, research regulators, and charities to make clinical research in the United Kingdom more efficient, more competitive, and more accessible. We expect these efforts to attract more commercial investment in clinical research and yield a broad and diverse portfolio of clinical trials in the UK, including clinical trials for cancer. The Department funded National Institute for Health and Care Research (NIHR) funds research and research infrastructure, which supports patients and the public to participate in high-quality research, including clinical research on cancer. NIHR research expenditure for all cancers was £133 million in 2023/24, reflecting its high priority. These investments are pivotal towards efforts to improve cancer prevention, treatment, and outcomes.